title: Functional characterization of PM6/13, a beta3-specific (GPIIIa/CD61) monoclonal antibody that shows preferential inhibition of fibrinogen binding over fibronectin binding to activated human platelets.
abstract: We report the characterization of a monoclonal antibody (MAb) PM6/13 which recognises glycoprotein IIIa (GPIIIa) on platelet membranes and in functional studies inhibits platelet aggregation induced by all agonists examined. In platelet-rich plasma, inhibition of aggregation induced by ADP or low concentrations of collagen was accompanied by inhibition of 5-hydroxytryptamine secretion. EC50 values were 10 and 9 microg/ml antibody against ADP and collagen induced responses respectively. In washed platelets treated with the cyclooxygenase inhibitor, indomethacin, PM6/13 inhibited platelet aggregation induced by thrombin (0.2 U/ml), collagen (10 microg/ml) and U46619 (3 microM) with EC50 = 4, 8 and 4 microg/ml respectively, without affecting [14C]5-hydroxytryptamine secretion or [3H]arachidonate release in appropriately labelled cells. Studies in Fura 2-labelled platelets revealed that elevation of intracellular calcium by ADP, thrombin or U46619 was unaffected by PM6/13 suggesting that the epitope recognised by the antibody did not influence Ca2+ regulation. In agreement with the results from the platelet aggregation studies, PM6/13 was found to potently inhibit binding of 125I-fibrinogen to ADP activated platelets. Binding of this ligand was also inhibited by two other MAbs tested, namely SZ-21 (also to GPIIIa) and PM6/248 (to the GPIIb-IIIa complex). However when tested against binding of 125I-fibronectin to thrombin stimulated platelets, PM6/13 was ineffective in contrast with SZ-21 and PM6/248, that were both potent inhibitors. This suggested that the epitopes recognised by PM6/13 and SZ-21 on GPIIIa were distinct. Studies employing proteolytic dissection of 125I-labelled GPIIIa by trypsin followed by immunoprecipitation with PM6/13 and analysis by SDS-PAGE, revealed the presence of four fragments at 70, 55, 30 and 28 kDa. PM6/13 did not recognize any protein bands on Western blots performed under reducing conditions. However Western blotting analysis with PM6/13 under non-reducing conditions revealed strong detection of the parent GPIIIa molecule, of trypsin treated samples revealed recognition of an 80 kDa fragment at 1 min, faint recognition of a 60 kDa fragment at 60 min and no recognition of any product at 18 h treatment. Under similar conditions, SZ-21 recognized fragments at 80, 75 and 55 kDa with the 55 kDa species persisting even after 18 h trypsin treatment. These studies confirm the epitopes recognised by PM6/13 and SZ-21 to be distinct and that PM6/13 represents a useful tool to differentiate the characteristics of fibrinogen and fibronectin binding to the GPIIb-IIIa complex on activated platelets.
authors.affiliation: Platelet Section, Thrombosis Research Institute, Chelsea, London, UK.
authors.forename: Y
authors.initials: Y
authors.lastname: Patel
authors.forename: S
authors.initials: S
authors.lastname: Rahman
authors.forename: A
authors.initials: A
authors.lastname: Siddiqua
authors.forename: J M
authors.initials: JM
authors.lastname: Wilkinson
authors.forename: V V
authors.initials: VV
authors.lastname: Kakkar
authors.forename: K S
authors.initials: KS
authors.lastname: Authi
mesh_terms: D000911:Antibodies, Monoclonal; D016718:Arachidonic Acid / Q000097:blood; D005340:Fibrinogen / Q000378:metabolism*; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D008297:Male; D015539:Platelet Activation; D010974:Platelet Aggregation / Q000276:immunology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000276:immunology*; D011485:Protein Binding; D012016:Reference Values; D014357:Trypsin
chemical_list: D000911:Antibodies, Monoclonal; D005353:Fibronectins; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D016718:Arachidonic Acid; D005340:Fibrinogen; D014357:Trypsin